Form 4: INSMED COO Roger Adsett Sells Over 10,000 Shares Under Pre-Arranged Trading Plan

INSMED Inc.'s Chief Operating Officer, Roger Adsett, sold 10,686 shares of common stock in two transactions on June 16, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Summary

• Roger Adsett, Chief Operating Officer of INSMED Inc. (INSM), sold a total of 10,686 shares of the company's common stock.
• The sales occurred on June 16, 2025, and were executed under a Rule 10b5-1 trading plan adopted on March 4, 2025.
• The first transaction involved the sale of 6,500 shares at a weighted average price of $98.50 per share, with prices ranging from $97.93 to $98.92.
• The second transaction involved the sale of 4,186 shares at a weighted average price of $99.32 per share, with prices ranging from $98.94 to $99.83.
• Following these transactions, Mr. Adsett's direct beneficial ownership of INSMED common stock stands at 130,637 shares.

Sentiment

Score: 5

Explanation: The sale of shares by a Chief Operating Officer, while reducing insider ownership, was conducted under a pre-arranged 10b5-1 trading plan, which typically mitigates the negative signal often associated with insider sales, leading to a neutral sentiment.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than a reaction to new, negative company-specific information.

Negatives

• An insider selling a significant number of shares, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces the insider's direct stake in the company.

Future Outlook

This document does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing details an individual insider stock transaction and does not provide information relevant to broader industry trends or competitors.

Related Party Transactions

• The sale of common stock by Roger Adsett, the Chief Operating Officer, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: May perceive the sale as a slight reduction in insider alignment, though the 10b5-1 plan context lessens this impact.
• Employees, Customers, Suppliers, Creditors: No direct impact is indicated by this filing.

Key Dates

Recommendation

Keywords

INSMED Inc., INSM, Roger Adsett, Chief Operating Officer, COO, Insider Trading, Form 4, SEC Filing, Stock Sale, Rule 10b5-1 Plan, Common Stock